Show Menu
Cheatography

Breast Cancer Sheet Cheat Cheat Sheet (DRAFT) by

breast cancer

This is a draft cheat sheet. It is a work in progress and is not finished yet.

One Minute Pitch

Breast cancer is a complex disease with great clinical and molecular hetero­geneity that requires accurate assessment of known breast cancer biomar­kers, such as HER2, estrogen receptor (ER), and proges­terone receptor (PgR), as well as the discovery of emerging potential targets, for the precise treatment of breast tumors. The RNAscope® in situ hybrid­ization assay offers a very reliable and robust method for the detection and validation of breast cancer­-re­lated markers within the tissue enviro­nment and can be performed on routinely available FFPE samples.

Applic­ations

Resolution of equivocal and hetero­geneous cases of HER2 expression
Validation of transc­riptome data
Sub-ce­llular locali­zation of RNA in breast cancer
Detection of lncRNAs in breast cancer
Precli­nical drug efficacy for breast cancer treatment
Assessment of potential prognostic markers for breast cancer

Known Breast Cancer Biomarkers

HER2 (ERBB2)
Estrogen receptor (ESR1)
Proges­terone receptor (PGR)
Triple negative breast cancer (TNBC): Negative for HER2, ER, and PR

Breast Cancer Subtypes

Marketing Materials

Breast Caner related public­ati­ons: http:/­/bi­t.l­y/2­q3dcKc
 

Examples of RNAscope in Breast Cancer Research

Reso­lution of equivocal and hetero­geneous cases of HER2 expres­sion: Standard HER2 testing methods are often hampered by equivocal testing and intrat­umoral hetero­gen­eity. Wang et al. developed a fully automated, quanti­tative ISH assay using the RNAscope® technology to quantify single­-cell HER2 mRNA levels. http:/­/bi­t.l­y/2­qGSIWG
Pati­ent­-st­rat­ifi­cation for treatment regime­ns: Vassil­ako­poulou et al. used the RNAscope® assay to assess HER2 mRNA as a predictor of benefit from trastu­zum­ab-­based chemot­herapy and to correlate it to HER2 protein and gene levels. http:/­/bi­t.l­y/2­rtsyHZ
Vali­dation of transc­riptome data and sub-ce­llular locali­zation of lncRNA in breast cancer: In their study Lin et al. selected lncRNA LINK-A as it shows frequently elevated expression in TNBC patients. RNAscope® ISH confirmed the array results, showing that expression of LINK-A was signif­icantly increased in TNBC tissues. http:/­/bi­t.l­y/2­qMojGT
Prec­linical drug efficacy for breast cancer treatm­ent: FGFR2 gene amplif­ication is found in 4% of triple­-ne­gative breast cancers (TNBC). In their study, Sommer et al. demons­trate the precli­nical efficacy of BAY118­7982, a novel FGFR2-­ant­ibody drug conjugate (ADC). http:/­/bi­t.l­y/2­rtlStB
Asse­ssment of HOTAIR as a prognostic breast cancer biomarker for breast cancer: High expression of the large intergenic non-coding RNA (lincRNA) HOTAIR has been shown to be a signif­icant predictor of poor prognosis and metastasis in breast carcin­omas. Gökmen­-Polar et al. showed that the prognostic role of HOTAIR is restricted to ER-/lymph node+ tumors, where its expression could be used as a potential prognostic marker. http:/­/bi­t.l­y/2­rKKHxs

Related Breast Cancer Probes

ABCB1 ABCG2 ADAM23 AKT1 APC AR ATM BAD BCL2 BIRC5 BRCA1 BRCA2 CCNA1 CCND1 CCND2 CCNE1 CDH1 CDH13 CDK2 CDKN1A CDKN1C CDKN2A CSF1 CST6 CTNNB1 CTSD EGF EGFR ERBB2 ESR1 ESR2 FOXA1 GATA3 GLI1 GRB7 GSTP1 HIC1 ID1 IGF1 IGF1R IGFBP3 IL6 JUN KRT18 KRT19 KRT5 KRT8 MAPK1 MAPK3 MAPK8 MGMT MKI67 MLH1 MMP2 MMP9 MUC1 MYC NME1 NOTCH1 NR3C1 PGR PLAU PRDM2 PTEN PTGS2 PYCARD RARB RASSF1 RB1 SERPINE1 SFN SFRP1 SLC39A6 SLIT2 SNAI2 SRC TFF3 TGFB1 THBS1 TP53 TP73 TWIST1 VEGFA XBP1
   

Help Us Go Positive!

We offset our carbon usage with Ecologi. Click the link below to help us!

We offset our carbon footprint via Ecologi